Galloway Capital Partners Announces 4.31% Stake in Babcock & Wilcox Enterprises, Inc.
Believes Babcock & Wilcox is Significantly Undervalued and Well-Positioned for Substantial Shareholder Value Creation MIAMI–(BUSINESS WIRE)–Galloway... Read more.
Manhattan Recognizes its Valued Partners at Momentum 2025
ATLANTA–(BUSINESS WIRE)–Manhattan Associates Inc. (NASDAQ: MANH) has announced the winners of the 2025 Manhattan Value PartnerTM (MVP) Excellence Awards.... Read more.
Jan Larsen Joins ValidMind as Chief Revenue Officer to Drive Next Phase of Growth
NEW YORK–(BUSINESS WIRE)–ValidMind, the leading platform for model risk management and AI governance, is proud to announce that Jan Larsen has joined... Read more.
Improzo Appoints Jane Urban as Chief Data & Analytics Officer
NEW YORK–(BUSINESS WIRE)–#ai–Improzo today announced the appointment of Jane Urban as Chief Data & Analytics Officer, effective June 2, 2025.... Read more.
IQVIA Announces Offering of Senior Notes
RESEARCH TRIANGLE PARK, N.C.–(BUSINESS WIRE)–IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV) today announced that its wholly-owned subsidiary, IQVIA Inc.... Read more.
Guardian Pharmacy Services Expands Pacific Northwest Footprint with Acquisition of Washington-based Mercury Pharmacy Services
ATLANTA–(BUSINESS WIRE)–Guardian Pharmacy Services, Inc. (NYSE: GRDN), one of the nation’s largest and most innovative long-term care (LTC) pharmacy... Read more.
Mary Campbell Joins Alliant Insurance Services’ Northwest Benefits Team
Veteran benefits consultant has deep expertise in alternative funding strategies for large, multi-state employers IRVINE, Calif.–(BUSINESS WIRE)–#AlliantInsurance–Mary... Read more.
Datavault AI to Participate in the “2025 Virtual Tech Conference: Discover the Innovations Reshaping Tomorrow” Virtual Conference Presented by Maxim Group LLC on Tuesday, June 3 – Thursday, June 5 at 9:00 a.m. EDT
Company fireside chat on June 4, at 1:00 p.m. EDT BEAVERTON, Ore.–(BUSINESS WIRE)–Datavault AI Inc. (NASDAQ: DVLT), leading the way in AI data experience,... Read more.
ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab reduced the risk of disease progression or death by 44% vs. THP as 1st-line therapy in patients with HER2-positive metastatic breast cancer in DESTINY-Breast09 Phase III trial
AstraZeneca and Daiichi Sankyo’s ENHERTU plus pertuzumab showed a median progression-free survival greater than three years First trial in more than a decade to... Read more.
Adtran expands Oscilloquartz atomic clock portfolio with lower-cost optical cesium solutions for wider market adoption
News summary: New Oscilloquartz models bring advanced optical pumping technology to telecom, defense, data center and metrology networks Adtran’s unique cesium... Read more.